Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
Cingulate Inc. announced the publication of peer-reviewed pharmacokinetic data for CTx-1301, its lead ADHD treatment candidate. The study shows that CTx-1301 delivers a unique trimodal release of dexmethylphenidate, offering rapid onset and sustained medication coverage throughout the active day with fewer adverse events than existing treatments. T…